SL1009

The trial enrolled 34 participants and did not meet its original primary endpoint. The FDA did not accept the proposed post hoc subgroup analyses or plasma lactate reduction as evidence establishing clinical benefit. The reported p=0.002 motor-function finding included longer treatment and the open-label extension, rather than demonstrating success on the randomized primary comparison. The p=0.66 analysis in more seriously affected participants was also not statistically significant. The report provides an interim disposition update, but not final participant disposition by randomized sequence. The original design publication describes an intention-to-treat strategy and planned imputation, but is not a complete account of the final analysis implementation.

This comparison reused the SL1009-01 treatment cohort and was not an independent randomized trial. The FDA identified inconsistent imputation, disease-severity imbalance, and an average temporal separation of 18 years between cohorts in its 2025 assessment. These limitations prevent interpreting the sponsor-reported p=0.027 as an established causal survival benefit. The subsequent resubmission announcement describes further analyses, including FDA-requested survival analyses, but this report contains no quantitative results from those additional analyses.

Only 11 of the 43 enrolled participants had pyruvate dehydrogenase deficiency, limiting direct applicability of the overall trial result to PDCD. The reported clinical outcomes did not improve. The subsequent open-label follow-up involved 36 participants from the earlier controlled trial and therefore does not represent an independent randomized replication. Peripheral nerve changes during long-term exposure require consideration alongside the short-term tolerability finding.

The trial enrolled 30 participants with MELAS and the A3243G mutation, not a PDCD population. It was terminated early, and the report documents peripheral neuropathy associated with 17 of 19 medication discontinuations. Its findings provide indirect safety information for chronic dichloroacetate exposure, but do not establish efficacy in PDCD.

This open-label safety cohort comprised 8 participants, including 3 with PDC deficiency, who had participated in earlier dichloroacetate trials. Treatment continued for 9.7 to 16.5 years. The selected long-term cohort and lack of a concurrent randomized comparison limit causal conclusions about efficacy or comparative safety. Stable laboratory measures did not exclude peripheral nerve findings that prompted dose reduction or temporary discontinuation in 3 participants.

The study followed 37 participants with various mitochondrial disorders using an open-label format and variable treatment duration. These observations do not provide a randomized estimate of treatment effect in PDCD. Diagnostic heterogeneity and unblinded outcome assessment limit attribution of neurologic changes to dichloroacetate.

The evidence concerns one critically ill neonate with PDHX-related disease. The temporal association between emergency investigational treatment, reduced lactic acid, and stabilization is not a controlled estimate of efficacy. A single case cannot establish comparative benefit, durability, or the frequency of adverse effects.

This single-case observation links treatment withdrawal with increased brain lactate and recurrent convulsions. It lacks a randomized comparison and cannot establish a general treatment effect, a validated surrogate relationship, or the incidence of treatment-related harm.

The biochemical reductions were reported in one participant. They do not establish a comparative clinical benefit, long-term neurologic effect, or survival effect. No systematic adverse-event results are included in the retrieved evidence.

The report describes two participants of different ages, without a randomized comparator. Reduced blood lactate in the first participant is a biochemical observation, not evidence of a general clinical treatment effect. Reported drug accumulation limits interpretation of biochemical response without considering exposure and toxicity.

The participant received multiple treatment modalities, and the reported lactate response was attributed to lipoic acid rather than isolated dichloroacetate exposure. Death at 1 year 8 months and the absence of a comparator prevent interpreting biochemical improvement as a demonstrated survival benefit.

This is a single-participant pharmacologic observation in mitochondrial encephalomyopathy with congenital lactic acidemia. The report does not provide a randomized comparison or establish that the participant had the target PDCD diagnosis. The exercise-related biochemical response therefore provides indirect evidence rather than an estimate of SL1009 clinical efficacy in PDCD.